Developing Drugs to Treat Rare Liver Diseases NASH PBC ACLF with Pascal Prigent GENFIT
Release Date: 05/14/2024
Empowered Patient Podcast
Joan Butters, CEO and Co-Founder of Xsolis works with health systems and health plans to automate medical necessity decisions and improve efficiency. Using data and AI, Xsolis helps clinicians make more informed decisions and reduces manual administrative work, resulting in time and cost savings and improved patient care. Addressing the challenges and pushback faced when introducing AI into healthcare, Joan emphasizes the importance of understanding the limitations and complexities of generative AI and the need for subject matter expertise in developing prompts to properly address friction...
info_outline Impact of AI on Reducing Waste and Friction in Healthcare Administration with Joan Butters XsolisEmpowered Patient Podcast
Joan Butters, CEO and Co-Founder of Xsolis works with health systems and health plans to automate medical necessity decisions and improve efficiency. Using data and AI, Xsolis helps clinicians make more informed decisions and reduces manual administrative work, resulting in time and cost savings and improved patient care. Addressing the challenges and pushback faced when introducing AI into healthcare, Joan emphasizes the importance of understanding the limitations and complexities of generative AI and the need for subject matter expertise in developing prompts to properly address friction...
info_outline Cancer Molecular Profiling Using Next-Generation Sequencing to Treat Rare Diseases with Sanjeev Redekar Apollomics TRANSCRIPTEmpowered Patient Podcast
Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. They are developing the drugs Vebreltinib and Uproleselan, which can be used as standalone treatments or in combination with other therapies to treat rare...
info_outline Cancer Molecular Profiling Using Next-Generation Sequencing to Treat Rare Diseases with Sanjeev Redekar ApollomicsEmpowered Patient Podcast
Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. They are developing the drugs Vebreltinib and Uproleselan, which can be used as standalone treatments or in combination with other therapies to treat rare...
info_outline Redefining Healthcare for Women Over 65 with Kristen Helton Herself Health TRANSCRIPTEmpowered Patient Podcast
Kristen Helton, CEO and Co-Founder of Herself Health, provides comprehensive primary care designed specifically for women over 65, considering the unique health challenges these women face. The emphasis is on the importance of addressing women's health beyond reproductive health and the need for tailored treatment and screening for conditions that affect women differently than men. Kristen notes the underrepresentation of women, especially older women, in clinical trials and the need for further investigation. They aim to reduce bias and improve the quality of care for older women by adopting...
info_outline Redefining Healthcare for Women Over 65 with Kristen Helton Herself HealthEmpowered Patient Podcast
Kristen Helton, CEO and Co-Founder of Herself Health, provides comprehensive primary care designed specifically for women over 65, considering the unique health challenges these women face. The emphasis is on the importance of addressing women's health beyond reproductive health and the need for tailored treatment and screening for conditions that affect women differently than men. Kristen notes the underrepresentation of women, especially older women, in clinical trials and the need for further investigation. They aim to reduce bias and improve the quality of care for older women by adopting...
info_outline Modifying Macrophages to Overcome Evasion by Cancer Cells and Educate Immune System with Robert Towarnicki SIRPant Immunotherapeutics TRANSCRIPTEmpowered Patient Podcast
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPĪ± expression, triggering them to eat cancer cells and educate other immune cells. Early evidence demonstrates potential effectiveness for various cancers, including non-Hodgkin's lymphoma and solid tumors. Robert emphasizes this therapy's scalability and cost advantages compared...
info_outline Modifying Macrophages to Overcome Evasion by Cancer Cells and Educate Immune System with Robert Towarnicki SIRPant ImmunotherapeuticsEmpowered Patient Podcast
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPĪ± expression, triggering them to eat cancer cells and educate other immune cells. Early evidence demonstrates potential effectiveness for various cancers, including non-Hodgkin's lymphoma and solid tumors. Robert emphasizes this therapy's scalability and cost advantages compared...
info_outline Power of AI and Data Analytics to Improve Patient Safety Risk Management with Jeff Surges RLDatix TRANSCRIPTEmpowered Patient Podcast
Jeff Surges, CEO of RLDatix, offers global cloud-based solutions for risk management, compliance management, and regulatory management in healthcare. To address patient safety, Jeff emphasizes the need for a collaborative workforce, data analytics, and AI. RLDatix uses technology to automate information gathering, facilitate incident reporting, and analyze data to determine proactive actions to prevent incidents and improve safety. Jeff explains, "The simplest analogy when I get asked this is: how does this relate to other industries? We all fly in airplanes, and we've...
info_outline Power of AI and Data Analytics to Improve Patient Safety Risk Management with Jeff Surges RLDatixEmpowered Patient Podcast
Jeff Surges, CEO of RLDatix, offers global cloud-based solutions for risk management, compliance management, and regulatory management in healthcare. To address patient safety, Jeff emphasizes the need for a collaborative workforce, data analytics, and AI. RLDatix uses technology to automate information gathering, facilitate incident reporting, and analyze data to determine proactive actions to prevent incidents and improve safety. Jeff explains, "The simplest analogy when I get asked this is: how does this relate to other industries? We all fly in airplanes, and we've...
info_outlinePascal Prigent, the CEO of GENFIT, a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as primary biliary cholangitis (PBC). The company is also developing assets in acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC.
Pascal explains, "In reality, we don't have any approved option in ACLF, which is actually quite dramatic because you have a high mortality rate. To give you a little bit of context, people are suffering from chronic liver disease, regardless of the etiology. It can be too much alcohol consumption, it could be NASH, it could be viral hepatitis. Any kind of chronic liver disease will give us all the same journey, if you will."
"First, you have an injury to the liver. Then you have a progressive liver scar. You have the setup of fibrosis, that fibrosis becomes worse and worse. It becomes bridging fibrosis, but at some point, it will become cirrhosis. And that cirrhosis is first compensated, and then one day it can decompensate, and on that already failing organ, you have a precipitating factor."
"That precipitating factor could be an infection, binge-drinking, or drug-induced trauma. That stress on an already sick organ will get the liver to decompensate, and that decompensation of the liver will trigger additional organ decomposition, and that's what ACLF is. It's a syndrome at the very end of chronic liver diseases."
#GENFIT #LiverDisease #NASH #PBC #ACLF #LiverFailure #Hepatitis #ChronicLiverDisease #RareDisease